Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2024-06-12 Capital/Financing Update
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
[발행조건확정]증권신고서(지분증권)
Capital/Financing Update Classification · 100% confidence The document is a 'Securities Registration Statement' (증권신고서) filed with the Financial Services Commission (금융위원회) in South Korea. It specifically details the finalization of issuance terms (발행조건확정) for a capital increase (유상증자). The document provides detailed financial calculations, subscription dates, and underwriting information related to the issuance of new shares. Since this is a formal regulatory filing detailing the terms of a capital raise and not merely an announcement of a report, it falls under the 'Capital/Financing Update' category.
2024-06-12 Korean
[기재정정]투자설명서
Capital/Financing Update Classification · 100% confidence The document is a '투자설명서 정정신고' (Amendment to the Securities Registration Statement) filed by HLB Life Science. It details changes to the offering price (from 11,890 KRW to 6,650 KRW) and updates related to the capital increase (rights offering). In the context of financial filings, a 'Securities Registration Statement' (증권신고서) and its amendments are classified under 'Capital/Financing Update' (CAP) as they pertain to the company's fundraising and capital structure changes.
2024-06-12 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Major Shareholding Notification Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in Korea. This type of filing is a standard regulatory disclosure for insider transactions or changes in major shareholdings by directors and executives. According to the provided definitions, 'Director's Dealing' (DIRS) covers reports of personal share transactions by company directors and executives, and 'Major Shareholding Notification' (MRQ) covers changes in significant share ownership. Given the document explicitly identifies the reporter as a major shareholder (10% 이상 주주) and details changes in their holdings, it fits the 'Director's Dealing' or 'Major Shareholding' category. Since it is a standard regulatory filing for insider/major shareholder activity, 'DIRS' is the most accurate classification.
2024-05-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is titled '주식등의 대량보유상황보고서' (Report on Large Shareholding of Stocks, etc.), which is the standard regulatory filing in South Korea for disclosing significant changes in share ownership (often referred to as the '5% rule' filing). This document details the change in shareholding percentage by HLB Co., Ltd. in HLB Life Science Co., Ltd. due to the allocation and sale of stock warrants. This fits the definition of a 'Major Shareholding Notification'.
2024-05-28 Korean
타인에대한담보제공결정
Capital/Financing Update Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding a 'Decision to Provide Collateral to Others' (타인에 대한 담보제공 결정). It details a financial transaction where the company provides collateral (shares of its subsidiary, HLB Energy) to secure debt for that subsidiary. This type of disclosure regarding financial guarantees, collateral, or capital-related commitments is classified under 'Regulatory Filings' (RNS) as it does not fit into specific categories like M&A, dividends, or share repurchases.
2024-05-23 Korean
[기재정정]증권신고서(지분증권) (2024.06)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서 정정신고' (Amendment to Securities Registration Statement) filed by HLB Life Science. It details specific amendments to a previously filed securities registration statement, including updates on clinical trial statuses (FDA CRL receipt), financial risks, and debt guarantees. In the context of Korean financial filings (DART), a '증권신고서' is a regulatory filing related to capital raising or public offerings, which falls under the 'Regulatory Filings' (RNS) category as it is a formal regulatory submission that does not fit into the other specific categories like 10-K or Earnings Release.
2024-05-23 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.